We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Simulations Plus Inc | NASDAQ:SLP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 48.21 | 46.90 | 76.65 | 0 | 09:05:09 |
Simulations Plus, Inc. (Nasdaq:SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 21st Annual Needham Growth Conference in New York City on Wednesday, January 16, 2019, at 8:40 a.m. ET (5:40 a.m. PT). In addition to his presentation, Mr. O’Connor will host one-on-one meetings throughout the day at the conference which will be held at the Lotte New York Palace Hotel.
A live webcast of the presentation will be accessible from the Events section of the Company's website (www.simulations-plus.com). The webcast will be archived for a period of 90 days. For more information about the conference or to schedule a one-on-one meeting with Mr. O’Connor, please contact Hayden IR at slp@haydenir.com.
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury, drug-induced kidney injury, and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com
Follow us on Twitter | LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20190110005182/en/
Simulations Plus Investor RelationsMs. Renee Bouche661-723-7723renee@simulations-plus.com
Hayden IRMr. Cameron Donahue651-653-1854cameron@haydenir.com
1 Year Simulations Plus Chart |
1 Month Simulations Plus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions